1Vannucchi AM, Guglielmelli P, Tefferi A. Advances in undersanding and management of myeloproliferative neoplasms [J]. CA Cancer J Clin, 2009 ;59 : 171-91.
3Harrison CN, Green AR. Essential thrombocythaemia [ J ]. Best Pract ResClin Haemato1,2006 ; 19:439-53.
4Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a largeeohort of patients with polyeythemia vera[J]. J Clin 0ncol,2005 ; 23:2224-32.
5Tefferi A. Primary myelofibrosis[J].CancerTreat Res,2008 ;142:29-49.
6Policitemia GIS. Folycythemia vera: the natural hmtory o1 121.5 patmnts followed for 20 years. Gruppo Italiano Studio Policitemia[ J]. Ann Intern Med, 1995 ;123:656-64.
7Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose as- pirin inpolycythemia vera[ J ]. N Engl J Med,2004 ;350 : 114-24.
8Harrison CN, Campbell PJ, Buck G,et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia [ J ]. N Engl J Med, 2005 ;353:33-45.
9Cervantes F, Passamonti F, Barosi G, Lite expectancy and prognostic tac- tors in the classic BCR/ABL-negative myeloproliferative disorders [J]. Leukemia ,2008:22:905-14.
